OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue
Tweet Send to a Friend
Stifel analyst David Grossman lowered the price target on OptimizeRX (NASDAQ: OPRX) to $17.00 (from $21.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
